NuVasive(R) Manufacturing, LLC., Expands U.S. Workforce to Drive Speed of Innovation(R)
SAN DIEGO, CA and DAYTON, OH--(Marketwired - Dec 20, 2013) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that NuVasive Manufacturing, LLC., (NML) will expand its workforce by more than 25 percent in 2014.
Acquired by NuVasive in May 2013, the 35,000-square-foot manufacturing facility produces the Company's PEEK, Armada®, and Precept® implants. The manufacturer currently employs more than 70 people and is hiring for positions ranging from skilled workers to senior management.
As NuVasive grows revenue toward $1 billion and beyond, NML's skilled workforce will be integral to NuVasive's initiative to reduce the time from conception of an innovative idea to market introduction.
On December 18, 2013, NuVasive Chairman and Chief Executive Officer Alex Lukianov was joined by the Mayor of Fairborn, Dan Kirkpatrick; Economic Development Director, Chris Wimsatt; Community Development Director, Mike Gebhart; and Fairborn Chapter Executive Director, Paul Newman, at NML for the official ribbon cutting ceremony.
"I am very excited to personally welcome NuVasive Manufacturing to the NUVA Family," said Chairman and Chief Executive Officer Alex Lukianov. "NML is vital to our market share taking strategy, and our drive to reduce product cost and improve operating profitability. NML is truly a world-class facility and I look forward to the contributions from our growing team of skilled Shareowners in Dayton. I am also thrilled that NuVasive can contribute to the growth of manufacturing jobs in the Dayton area."
Prior to the ribbon cutting ceremony, Mayor Kirkpatrick stated, "I look forward to a long-term and rewarding relationship with NuVasive and I am very pleased that NML will bring new jobs to the Dayton and Fairborn area."
To search for current NuVasive Manufacturing job openings please visit: www.nuvasive.com/careers
About NuVasive Manufacturing, LLC.
NuVasive Manufacturing, LLC., (NML) is based in Dayton, Ohio and produces the Company's PEEK, Armada®, and Precept® spinal implants. As one of NuVasive's significant implant suppliers, NML and has seamlessly integrated into the NuVasive culture helping to launch the Company's innovative solutions.
About NuVasive
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-Up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties are described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
